12:00 AM
 | 
Apr 06, 2009
 |  BC Week In Review  |  Company News  |  Deals

EffRx Inc., Nycomed Group A/S deal

The companies added new territories to Nycomed's exclusive rights to develop and commercialize EffRx's EX101 to treat musculoskeletal diseases, except hypercalcemia of malignancy. Nycomed now has rights to develop and commercialize the effervescent formulation of alendronate worldwide, excluding...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >